- Home
- GMAB vs RPM Comparison
GMAB vs RPM Comparison
Compare GMAB & RPM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- RPM
- Stock Information
- Founded
- GMAB 1999
- RPM 1947
- Country
- GMAB Denmark
- RPM United States
- Employees
- GMAB N/A
- RPM N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- RPM Paints/Coatings
- Sector
- GMAB Health Care
- RPM Consumer Discretionary
- Exchange
- GMAB Nasdaq
- RPM Nasdaq
- Market Cap
- GMAB 13.7B
- RPM 14.6B
- IPO Year
- GMAB N/A
- RPM N/A
- Fundamental
- Price
- GMAB $21.45
- RPM $113.29
- Analyst Decision
- GMAB Buy
- RPM Buy
- Analyst Count
- GMAB 8
- RPM 12
- Target Price
- GMAB $37.80
- RPM $127.33
- AVG Volume (30 Days)
- GMAB 1.6M
- RPM 887.9K
- Earning Date
- GMAB 08-07-2025
- RPM 07-24-2025
- Dividend Yield
- GMAB N/A
- RPM 1.78%
- EPS Growth
- GMAB 276.80
- RPM 15.12
- EPS
- GMAB 18.36
- RPM 4.99
- Revenue
- GMAB $3,230,902,140.00
- RPM $7,298,832,000.00
- Revenue This Year
- GMAB $747.74
- RPM $0.64
- Revenue Next Year
- GMAB $14.81
- RPM $3.86
- P/E Ratio
- GMAB $11.66
- RPM $22.69
- Revenue Growth
- GMAB 25.43
- RPM N/A
- 52 Week Low
- GMAB $17.24
- RPM $95.28
- 52 Week High
- GMAB $28.56
- RPM $141.79
- Technical
- Relative Strength Index (RSI)
- GMAB 53.47
- RPM 54.38
- Support Level
- GMAB $20.23
- RPM $110.60
- Resistance Level
- GMAB $21.90
- RPM $115.35
- Average True Range (ATR)
- GMAB 0.35
- RPM 2.24
- MACD
- GMAB 0.06
- RPM 0.45
- Stochastic Oscillator
- GMAB 73.52
- RPM 77.72
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About RPM RPM International Inc.
RPM International Inc manufactures and sells a variety of paints, coatings, and adhesives. The firm organizes itself into four segments based on product type. The construction products group sells coatings, roofing, insulation, and other products to distributors, contractors, and end consumers globally. The performance coatings group produces coatings that are used in construction and industrial applications like floorings and corrosion control. The consumer group sells paint, finishes, and similar products to individual consumers through hardware and craft stores. The specialty products group sells a line of products ranging from niche applications of the other groups to marine finishes, to edible food colorings. The majority of revenue comes from North America.